biohit fda

In the United States, the Food and Drug Administration (FDA) has
already approved the GastroPanel tests for Gastrin-17 and H. pylori
antibodies, but the tests for Pepsinogen I and II are still being
evaluated and additional research required by the FDA is being conducted.
Registration processes are likewise underway in Ukraine, South Korea and
Brazil. In addition, GastroPanel has previously been granted market
authorisation in India, Canada and Russia. All of the company's
diagnostics products can be sold in the EU. 

Feb 17, 2006 10:00
FINANCIAL STATEMENT REPORT OF BIOHIT GROUP 1 JANUARY TO 31 DECEMBER 2005 

biohit financial statement

fda

Gastroenterology and Urology Devices Panel Oct 20, 2006  

Mvh biohit